<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04241367</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2019-0027</org_study_id>
    <nct_id>NCT04241367</nct_id>
  </id_info>
  <brief_title>Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy</brief_title>
  <official_title>Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for verification of predictive biomarkers for pancreatic cancer treatment using
      multi-center liquid biopsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer
      patients.

        -  Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA
           extracted from collected patient samples.

        -  Correlation analysis of KRAS mutation results with clinical data.

      Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.

        -  Gene panel composition for pancreatic cancer therapeutic target determination and
           monitoring.

        -  A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic
           cancer patients.

        -  Comparative analysis of panel results and quantitative KRAS mutations and evaluation of
           clinical applicability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical applicability of KRAS mutations</measure>
    <time_frame>Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months</time_frame>
    <description>Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Discovery of biomarkers through ctDNA panel</measure>
    <time_frame>Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months</time_frame>
    <description>Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.</description>
  </primary_outcome>
  <enrollment type="Anticipated">662</enrollment>
  <condition>Pancreas Adenocarcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inpatient or outpatient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathologically confirmed pancreatic adenocarcinoma.

        Exclusion Criteria:

          -  Patients disagree with the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sangmyung Woo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sangmyung Woo, MD</last_name>
    <phone>82 31 920 1733</phone>
    <email>wsm@ncc.re.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong‚Äêgu,</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SANGMYUNG WOO, MD</last_name>
      <phone>82-31-920-1733</phone>
      <email>wsm@ncc.re.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 22, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Sang Myung Woo</investigator_full_name>
    <investigator_title>Chief, Senior Scientist</investigator_title>
  </responsible_party>
  <keyword>Pancreas Adenocarcinoma</keyword>
  <keyword>Circulating-tumor DNA</keyword>
  <keyword>KRAS mutations</keyword>
  <keyword>Cancer Panel</keyword>
  <keyword>Prognostic markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

